| Literature DB >> 32856156 |
Francesco Porpiglia1, Andrea Mari2, Daniele Amparore1, Cristian Fiori1, Alessandro Antonelli3, Walter Artibani4, Pierluigi Bove5, Eugenio Brunocilla6,7, Umberto Capitanio8, Luigi Da Pozzo9, Fabrizio Di Maida1, Paolo Gontero10, Nicola Longo11, Giancarlo Marra10, Bernardo Rocco12,13, Riccardo Schiavina6, Claudio Simeone3, Salvatore Siracusano4, Riccardo Tellini1, Carlo Terrone14, Donata Villari15, Vincenzo Ficarra16, Marco Carini1, Andrea Minervini17,18.
Abstract
BACKGROUND: Aim of this study was to evaluate and compare perioperative outcomes of transperitoneal (TP) and retroperitoneal (TR) approaches in a multi-institutional cohort of minimally invasive partial nephrectomy (MI-PN).Entities:
Keywords: Minimally invasive partial nephrectomy; Renal cell carcinoma; Retroperitoneal; Surgical approach; Transperitoneal
Mesh:
Year: 2020 PMID: 32856156 PMCID: PMC8263535 DOI: 10.1007/s00464-020-07919-4
Source DB: PubMed Journal: Surg Endosc ISSN: 0930-2794 Impact factor: 4.584
Comparison of the preoperative characteristics of 413 patients treated with retroperitoneal minimally invasive partial nephrectomy with selected matched 413 patients treated with transperitoneal minimally invasive partial nephrectomy for renal tumors within the RECORD 2 project
| RECORD 2 project—preoperative tumor and patient data | Surgical access | ||||
|---|---|---|---|---|---|
| Transpertioneal ( | Retroperitoneal ( | ||||
| Gender, | |||||
| Male | 271 | 65.6% | 280 | 67.8% | 0.67 |
| Female | 142 | 34.4% | 133 | 32.2% | |
| Age (years), median IQR | 64.8 | 56.2–72.4 | 64.6 | 55.9–72.3 | 0.71 |
| BMI, median IQR | 25.9 | 23.9–28.7 | 25.8 | 23.7–28.4 | 0.95 |
| ECOG score, | |||||
| 0 | 311 | 75.3% | 315 | 76.3% | 0.69 |
| ≥ 1 | 92 | 24.6% | 98 | 23.7% | |
| CCI score, median IQR | 1 | 0–2 | 1 | 0–2 | 0.71 |
| ASA PS score, median IQR | 2 | 2–3 | 2 | 2–3 | 0.82 |
| Indication, | |||||
| Elective | 312 | 75.5% | 287 | 69.6% | 0.24 |
| Relative | 86 | 20.8% | 103 | 24.9% | |
| Absolute | 19 | 3.7% | 23 | 5.5% | |
| Clinical T, | |||||
| T1a | 330 | 79.9% | 331 | 80.1% | 0.82 |
| T1b | 83 | 20.1% | 82 | 19.9% | |
| Tumor side, | |||||
| Right | 202 | 48.9% | 194 | 47.0% | 0.93 |
| Left | 211 | 51.1% | 219 | 53.0% | |
| Clinical diameter, median IQR | 3.2 | 1.9–4.6 | 3.1 | 1.8–4.5 | 0.63 |
| Tumor site, | |||||
| Mesorenal | 271 | 65.6% | 278 | 67.3% | 0.18 |
| Polar | 142 | 34.4% | 135 | 32.7% | |
| Tumor growth pattern, | |||||
| ≥ 50% Exophytic | 229 | 55.4% | 240 | 58.1% | 0.41 |
| < 50% Exophytic | 160 | 38.7% | 147 | 35.6% | |
| Entirely endophytic | 24 | 5.8% | 26 | 6.3% | |
| PADUA Score, median IQR | 7.0 | 7.0–8.0 | 7.0 | 7.0–8.0 | 0.69 |
| PADUA complexity group, n. % | |||||
| Low (6–7) | 244 | 59.1% | 251 | 60.8% | 0.78 |
| Medium (8–9) | 155 | 37.5% | 146 | 35.4% | |
| High (≥ 10) | 14 | 3.4% | 16 | 3.9% | |
| Tumor localization, | |||||
| Lateral margin | 139 | 33.7% | 143 | 34.6% | 0.26 |
| Medial margin | 49 | 11.8% | 46 | 11.3% | |
| Anterior face | 41 | 9.9% | 37 | 9.0% | |
| Posterior face | 183 | 44.3% | 187 | 45.0% | |
| Peri-hilar | 1 | 0.2% | 0 | 0% | |
| Preoperative hemoglobin, mean SD | 14.5 | 13.4–15.3 | 14.2 | 13.3–15.2 | 0.83 |
| Preoperative creatinine (mg/dl), mean SD | 0.9 | 0.80–1.00 | 0.9 | 0.80–1.10 | 0.19 |
| Preoperative eGFR, median IQR | 85.1 | 70.3–96.6 | 82.8 | 66.8–99.5 | 0.67 |
Comparison of the centers data and the intraoperative characteristics of 413 patients treated with retroperitoneal minimally invasive partial nephrectomy with selected matched 413 patients treated with transperitoneal minimally invasive partial nephrectomy for renal tumors within the RECORD 2 project
| RECORD 2 project—intraoperative center and surgical data | Surgical access | ||
|---|---|---|---|
| Transpertioneal ( | Retroperitoneal ( | ||
| PN/RN ratio, median (IQR) | 66.6% (50.6–78%) | 74.0% (66.6–87.9%) | < 0.0001 |
| Number of PN/year of the center of treatment, median (IQR) | 56 (35–79) | 71 (44–84) | < 0.0001 |
| Center volume, | |||
| > 30 PN/year | 313 (75.8%) | 331 (80.1%) | 0.001 |
| > 50 PN/year | 256 (62.0%) | 315 (76.3%) | 0.001 |
| Surgical approach | |||
| Laparoscopic | 281 (68.0%) | 279 (67.5%) | 0.67 |
| Robotic | 132 (32.0%) | 134 (33.5%) | |
| Technique, | |||
| Enucleation | 173 (41.9%) | 169 (40.9%) | 0.77 |
| Standard PN | 240 (58.1%) | 244 (59.1%) | |
| Hilar clamping, | |||
| Not performed | 198 (47.9%) | 213 (51.6%) | 0.29 |
| Performed | 215 (52.1%) | 200 (48.4%) | |
| Ischemia time(min), median (IQR) | 19 (14–24) | 20 (15–25) | 0.14 |
| EBL (cc), median (IQR) | 100 (100–200) | 150 (100–143) | 0.10 |
| Extended peritoneum opening, | 32 (7.7%) | – | – |
| Intraoperative time, median (IQR) | 115 (96–130) | 150 (120–180) | < 0.0001 |
| Intraoperative overall complications, | 21 (5.0%) | 9 (2.1%) | 0.03 |
| Intraoperative surgical complications, | 18 (4.3%) | 7 (1.7%) | 0.04 |
| Vascular lesion, | 9 (2.1%) | 4 (0.8%) | – |
| Spleen injury, | 2 (0.4%) | – | – |
| Conversion to open procedure, | 4 (0,8%) | 2 (0.4%) | – |
| Bleeding from renal resection bed, | 3 (0.2%) | 1 (0.2%) | – |
| Intraoperative medical complications, | 3 (0.7%) | 2 (0.5%) | 0.64 |
| Miocardial infarction, | 2 (0.4%) | 1 (0.2%) | – |
| Arrytmias, | 1 (0.2%) | 1 (0.2%) | – |
Fig. 1Distribution of transperitoneal and retroperitoneal surgical procedures according to each single centre after propensity score matching analysis
Comparison of the postoperative outcomes of 413 patients treated with retroperitoneal minimally invasive partial nephrectomy with selected matched 413 patients treated with transperitoneal minimally invasive partial nephrectomy for renal tumors within the RECORD 2 project
| RECORD 2 project—report of early postoperative and functional follow-up outcomes | Surgical access | ||
|---|---|---|---|
| Transpertioneal (n = 413) | Retroperitoneal (n = 413) | ||
| Surgical postoperative complications, | 29 (7%) | 25 (6.1%) | 0.57 |
| Surgical clavien 2 postop complications, | 12 (2.9%) | 11 (2.7%) | |
| Surgical clavien 3a, postop complications, | 11 (2.7%) | 10 (2.4%) | |
| Surgical clavien 3b, postop complications, | 3 (0.7%) | 4 (1%) | |
| Surgical clavien 4a, postop complications, | 3 (0.7%) | 0 | |
| Transfusions, | 21 (5.1%) | 15 (3.6%) | |
| Deep vein thrombosis, | 1 (0.2%) | 0 | |
| Superselective embolization, | 8 (2.0%) | 7 (1.7%) | |
| Urinary fistula treated without stenting, | 4 (0.8%) | 4 (0.8%) | |
| Urinary fistula treated with stenting or nephrostomy tube, | 2 (0.4%) | 1 (0.2%) | |
| Medical postoperative complications, | 16 (3.9%) | 14 (3.4%) | 0.48 |
| Respiratory complications, | 8 (2.0%) | 8 (2.0%) | |
| Cardiologic complications, | 7 (1.7%) | 5 (1.2%) | |
| Acute pulmonary embolism, | 1 (0.2%) | 1 (0.2%) | |
| Drainage duration (days), median (IQR) | 3 (2–4) | 2 (1–2) | < 0.0001 |
| Time to bowel canalization, median (IQR) | 3 (2–5) | 2 (1–3) | < 0.0001 |
| Hospital length of stay (days), median (IQR) | 3 (3–4) | 2 (2–3) | < 0.0001 |
| Malignant tumors, | 308 (74.6%) | 310 (75.1%) | 0.82 |
| Positive surgical margins, | 21 (5.1%) | 23 (5.6%) | 0.73 |
| Preoperative—1st postoperative day Δ hemoglobin (mg/dL), median (IQR) | 1.7 (1.1–3.0) | 1.5 (0.9–2.7) | 0.48 |
| Preoperative—3rd postoperative day Δ hemoglobin (mg/dL), median (IQR) | 2.2 (1.4–3.1) | 1.8 (1.0–2.9) | 0.25 |
| 1st POD creatinine (mg/dl), median (IQR) | 1.0 (0.8–1.2) | 1.0 (0.8–1.3) | 0.18 |
| 1st POD eGFR, median (IQR) | 76 (61.0–89.0) | 73 (57.2–89.0) | 0.08 |
| Preoperative—1st POD Δ eGFR, median (IQR) | 10.3 (0.0–20.8) | 10.4 (0.0–22.5) | 0.69 |
| Preoperative—3rd POD Δ eGFR, median (IQR) | 10.1 (0.0–20.1) | 9.0 (0.0–20.7) | 0.53 |
| Preoperative—6th month Δ eGFR, median (IQR) | 8.7 (0.3–15.9) | 8.8 (0.4–15.0) | 0.65 |
| Preoperative—12th month Δ eGFR, median (IQR) | 9.2 (4.1–21.5) | 9.3 (3.4–20.8) | 0.67 |
| Preoperative—24th month Δ eGFR, median (IQR) | 9.6 (4.4–20.5) | 9.8 (4.5–20.0) | 0.68 |